» Articles » PMID: 29271806

Prospective Evaluation of Standalone XEN Gel Implant and Combined Phacoemulsification-XEN Gel Implant Surgery: 1-Year Results

Overview
Journal J Glaucoma
Date 2017 Dec 23
PMID 29271806
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the safety and efficacy of XEN gel implant (Allergan Inc., Irvine) as a standalone versus combined XEN-Phacoemulsification surgery (XEN+cataract) in glaucoma patients.

Methods: Prospective, interventional study. One-hundred forty-nine eyes (113 patients) with open-angle glaucoma and uncontrolled intraocular pressure (IOP) despite medical treatment were enrolled at a tertiary glaucoma center and followed up for a minimum of 1 year. Approximately two-thirds of patients underwent combined XEN+cataract surgery, while the remainder had XEN alone surgery. Primary outcome was a 20% or more decrease in IOP from medicated baseline at 1 year. Mean IOP, mean number of medications at last follow-up, and incidence of adverse effects were analyzed.

Results: Of 149 enrolled eyes, data of 87 (58%) were available at 1 year. A total of 109 (73.2%) eyes underwent XEN+cataract surgery and 40 (26.8%) XEN alone surgery. Mean medicated IOP was 20.0±7.1 at baseline and 13.9±4.3 mm Hg at 1 year (P<0.01), a 31% IOP reduction. Mean medications dropped from 1.9±1.3 preoperatively to 0.5±0.8 at 1 year (P<0.001). In total, 62.1% of patients achieved a ≥20% IOP reduction; this proportion was higher in the XEN alone group. 57.7% of eyes achieved complete success (without any antiglaucoma medications) and 71.1% qualified success (with or without medications) when IOP<16 mm Hg was considered as the definition of success. In all, 37% of patients required needling intervention. Adverse effects included bleb revision in 5 eyes, choroidal detachment in 2 eyes, and second glaucoma surgery in 9 eyes.

Conclusions: The XEN gel implant as a standalone procedure or combined with cataract surgery demonstrated safe and sustained IOP reduction after 1 year.

Citing Articles

Effectiveness and safety of the XEN45 gel stent compared to trabeculectomy in primary open-angle glaucoma: the Gold-Standard Pathway Study.

Ahmed I, Vera V, Stalmans I, Fea A, Mansouri K, Gu X BMJ Open Ophthalmol. 2025; 10(1).

PMID: 39915236 PMC: 11804186. DOI: 10.1136/bmjophth-2024-001696.


Update on Surgical Techniques Best Practices to Optimize Outcomes Following Gel Stent Implantation.

Vera V, Sheybani A, Panarelli J, Grover D, Lee J, Craven E Clin Ophthalmol. 2025; 19:325-347.

PMID: 39911142 PMC: 11794994. DOI: 10.2147/OPTH.S487718.


Results of XEN45 Gel Stent Implantation in the Treatment of Primary Open-Angle Glaucoma Using 5, 10 or 20 g Mitomycin C: A Pilot Study.

Reichel F, Guggenberger V, Faber H, Neubauer J, Voykov B J Ophthalmol. 2024; 2024:3895054.

PMID: 39492955 PMC: 11531357. DOI: 10.1155/2024/3895054.


Long-term effectiveness and safety of XEN45 in open-angle glaucoma patients.

Carassa R, Corsini G, Triolo G Int Ophthalmol. 2024; 44(1):310.

PMID: 38960998 DOI: 10.1007/s10792-024-03234-2.


XEN45 Implant in Medically Controlled vs. Uncontrolled Eyes-Differential IOP Changes in Real-Life Conditions.

Julio G, Larena R, Marmol M, Soldevila A, Canut M, Pavan J J Clin Med. 2024; 13(12).

PMID: 38929940 PMC: 11204868. DOI: 10.3390/jcm13123406.